Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 3Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Hemangiosarcoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Desmoid Tumors 1Carcinoma, Intraductal, Noninfiltrating 1

Interventions

Paclitaxel 42Carboplatin 37Bevacizumab 29liposomal doxorubicin 20Taxes 18Specimen Handling 18pembrolizumab 16olaparib 16Magnetic Resonance Spectroscopy 16Gemcitabine 16Topotecan 13Immunoglobulin G 12Disulfides 12Biopsy 11niraparib 8mirvetuximab soravtansine 8Nivolumab 7Doxorubicin 7Cyclophosphamide 6Cisplatin 6Drug Therapy 5130-nm albumin-bound paclitaxel 5cemiplimab 4cediranib 4Letrozole 4Injections 4Docetaxel 41-dodecylpyridoxal 4sarilumab 3rucaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × 4-hydroxy-N-desmethyltamoxifen × 1 year × Clear all
NCT01273168 2025-12-23

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
40 enrolled
BreastGynecologicSarcoma

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡